Harpoon Therapeutics Inc
Change company Symbol lookup
Select an option...
HARP Harpoon Therapeutics Inc
VIRC Virco Mfg Corp
RVLP RVL Pharmaceuticals PLC
TRGP Targa Resources Corp
RCRT Recruiter.Com Group Inc
VGAS Verde Clean Fuels Inc
DHHC DiamondHead Holdings Corp
EJH E-Home Household Service Holdings Ltd
FLGC Flora Growth Corp
HL Hecla Mining Co
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.

Closing Price
$0.6725
Day's Change
-0.0145 (-2.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6997
Day's Low
0.631
Volume
(Average)
Volume:
344,365

10-day average volume:
328,263
344,365

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Enviva Inc., of Class Actions Lawsuit and Upcoming Deadline - EVA

4:16 pm ET January 1, 2023 (Globe Newswire) Print
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Enviva Inc., of Class Actions Lawsuit and Upcoming Deadline - EVAGlobeNewswireJanuary 01, 2023

NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Enviva Inc. (NYSE: EVA), and certain officers. The class action, filed in the United States District Court for the District of Maryland, and docketed under 22-cv-02844, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Enviva securities between February 21, 2019 and October 11, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchase or otherwise acquired Enviva securities, you have until January 2, 2023 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Enviva, formerly known as Enviva Partners, LP, develops, constructs, acquires, and owns and operates, fully contracted wood pellet production plants. The Company's products are used as a substitute for coal in power generation, and combined heat and power plants. Significantly, Enviva touts itself as a "growth-oriented" environmental, social, and governance ("ESG") company with a "platform to generate stable and growing cash flows."

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Enviva had misrepresented the environmental sustainability of its wood pellet production and procurement; (ii) Enviva had similarly overstated the true measure of cash flow generated by the Company's platform; (iii) accordingly, Enviva had misrepresented its business model and the Company's ability to achieve the level of growth that Defendants had represented to investors; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

On October 12, 2022, during pre-market hours, Blue Orca Capital ("Blue Orca") published a report on Enviva (the "Blue Orca Report"). Among other allegations, the Blue Orca Report stated that "new discovered data suggests . . . the company is flagrantly greenwashing its wood procurement" and characterized Enviva's claim to be a "pure play ESG Company with a healthy, self-funded dividend and cash flows to provide a platform for future growth" as "nonsense on all counts." Moreover, the Blue Orca Report alleged that "Enviva is a dangerously levered serial capital raiser whose deteriorating cash conversion and unprofitability will drain it of cash next year" and is "a product of deranged European climate subsidies which incentivize the destruction of American forests so that European power companies can check a bureaucratic box."

On this news, Enviva's stock price fell $7.74 per share, or 13.13%, to close at $51.23 per share on October 12, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980



comtex tracking

COMTEX_421731941/2010/2023-01-01T16:16:27

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.